182 related articles for article (PubMed ID: 29192558)
1. Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.
Niscola P; Scaramucci L; Giovannini M
Immunotherapy; 2018 Jan; 10(1):5-7. PubMed ID: 29192558
[No Abstract] [Full Text] [Related]
2. Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Newland A; Lee EJ; McDonald V; Bussel JB
Immunotherapy; 2018 Jan; 10(1):9-25. PubMed ID: 28967793
[TBL] [Abstract][Full Text] [Related]
3. Fostamatinib: First Global Approval.
Markham A
Drugs; 2018 Jun; 78(9):959-963. PubMed ID: 29869203
[TBL] [Abstract][Full Text] [Related]
4. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
5. Fostamatinib for the treatment of chronic immune thrombocytopenia.
Connell NT; Berliner N
Blood; 2019 May; 133(19):2027-2030. PubMed ID: 30803989
[TBL] [Abstract][Full Text] [Related]
6. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
7. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
Lee EJ; Izak M; Bussel JB
Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
[TBL] [Abstract][Full Text] [Related]
8. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
9. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.
Podolanczuk A; Lazarus AH; Crow AR; Grossbard E; Bussel JB
Blood; 2009 Apr; 113(14):3154-60. PubMed ID: 19096013
[TBL] [Abstract][Full Text] [Related]
10. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
12. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
13. Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia.
McBride A; Nayak P; Kreychman Y; Todd L; Duliege AM; Mehta AR
Am J Manag Care; 2019 Nov; 25(19 Suppl):S347-S358. PubMed ID: 31809006
[TBL] [Abstract][Full Text] [Related]
14. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
[TBL] [Abstract][Full Text] [Related]
15. New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.
Clemons Bankston P; Al-Horani RA
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31226783
[TBL] [Abstract][Full Text] [Related]
16. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
[TBL] [Abstract][Full Text] [Related]
17. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
Boers M
Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
[No Abstract] [Full Text] [Related]
18. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
Yang R; Lin L; Yao H; Ji O; Shen Q
Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
[TBL] [Abstract][Full Text] [Related]
20. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
